Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Eligible age
18–80 yrs
Accepts
All genders
Locations
17 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).
Sponsor: Novartis Pharmaceuticals
Where it's recruiting
Birmingham
Sun City West
Beverly Hills · West Hills
Boca Raton · Jacksonville · Maitland · Miami …
Park Ridge
Muncie
Covington · Metairie
Bowie · Ft. Washington
Detroit · Flint · Midland
Las Vegas
Summit
Winston-Salem
Source: ClinicalTrials.gov · NCT06813911 · last updated 2026-08-07